In the Specification:

Please amend the specification as shown:

Please delete the paragraphs on page 2, line 6 to page 3, line 3 and replace them with the following paragraphs:

MBPCs for use in the treatment of HIV infections were first described by J-M. Sabatier et al in WO 95/07929. The MBPCs described therein have peptides which contain the sequence GPGR **(SEQ ID NO: 1)** (from the V3 loop of the surface envelope glycoprotein gp120 of HIV) preceded by from 0 to 4 amino acid residues and succeeded by from 2 to 4 amino acid residues. The amino acid sequences IGPGR **(SEQ ID NO: 2)** and IXXGPGR **(SEQ ID NO: 3)** (where X is an amino acid residue) are excluded. The most preferred of these MBPCs has a lysine residue core with eight peptides GPGRAF **(SEQ ID NO: 4)** bonded thereto. It may be represented as $(GPGRAF)_8$-K_4-K_2-K-βA-OH **(SEQ ID NOS 4 & 5)**, the OH terminal indicating the carboxyl group of the β-alanine. That carboxyl group may alternatively be modified to form a carboxamide terminal. This compound is referred to herein as SPC3.

In WO 98/29443, J-M Sabatier et al described further MBPCs which may be effective in the treatment of HIV infection. These use peptides derived from the HIV envelope transmembrane glycoprotein gp41. The peptides contain the sequence RQGY **(SEQ ID NO: 6)** preceded by from 0 to 4 amino acid residues and succeeded by from 2 to 4 amino acid residues. The most preferred of these MBPCs has a lysine residue core with eight peptides RQGYSPL **(SEQ ID NO: 7)** bonded thereto. It may be represented as $(RQGYSPL)_8$-K_4-K_2-K-βA-OH **(SEQ ID NOS 7 & 5)**, the OH terminal indicating the carboxyl group of the β-alanine. That carboxyl group may alternatively be modified to form a carboxamide terminal. This compound is referred to herein as RL, although it has in the past also been referred to as SPC RL and as RL41.

Subsequently to WO 98/29443, it was established that the MBPC $(RQGYSPL)_2$-K-βA **(SEQ ID NO: 7)** (hereinafter RL dimer) is effective but that the MBPC $(RQGYSP)_2$-K-βA **(SEQ ID NO: 8)** is less so. This was thought to confirm the lower limit of 6 amino acids in the peptide branches of the MBPCs. However, K Mabrouk et al showed in WO 03/095479 that some shorter peptides could be used, in particular $(RQGYS)_2$-K-βA-OH **(SEQ ID NO: 9)**

(hereinafter RS, but in the past also referred to as Short RL) and $(RQGY)_8$-K_4-K_2-K- βA-OH **(SEQ ID NOS 6 & 5)**.

SPC3 and RL both have 8 branches and are described as octomers. RS has two branches, and is described as a dimer. None of the monomers, that is the linear peptides GPGRAF **(SEQ ID NO: 4)**, RQGYSPL **(SEQ ID NO: 7)** and RQGYS **(SEQ ID NO: 9)**, has ever shown any activity.

Please delete the paragraphs on page 3, line 24 to page 4, line 10 and replace them with the following paragraphs:

The invention provides a compound comprising a water soluble antiviral peptide including one of the sequences GPG and RQGY **(SEQ ID NO: 6)** and, bonded to the C-end of the peptide, a terminator which is either (a) an ω-amino-fatty acid having from 4 to 10 carbon atoms and from 0 to 2 carbon-carbon double bonds or (b) a peptidic cell membrane penetrating agent.

The antiviral peptide may be an MBPC with a lysine core matrix. In such a case the terminator is bonded to the root lysine residue. The MBPCs described above may be used, that is to say SPC3 which has 8 branches of GPGRAF **(SEQ ID NO: 4)**, RL which has 8 branches of RQGYSPL **(SEQ ID NO: 7)** and RS which has 2 branches of RQGYS **(SEQ ID NO: 9)**. However, the improvement resulting from the bonding of the terminator to the C-end of the antiviral peptide is so great that SPC3 and RL can be reduced to two branches (SPC3 dimer and RL dimer, respectively), or even to one branch (SPC3 monomer and RL monomer, respectively), while RS may also be reduced to one branch (RS momomer). Further work has even indicated that SPC3 monomer (GPGRAF) **(SEQ ID NO: 4)** may be shortened to GRGRA **(SEQ ID NO: 10)**, GPGR **(SEQ ID NO: 1)** or GPC. As these are much smaller molecules, they are much easier and cheaper to make and are preferred for that reason.

Please delete the paragraph on page 5, lines 5-9 and replace it with the following paragraph:

We also synthesized shortened peptides related to SPC3 monomer, which is GPGRAF **(SEQ ID NO: 4)**, in particular GRGRA **(SEQ ID NO: 10)**, GPGR **(SEQ ID NO: 1)** and GPG and tested these with a δ-aminovaleric acid terminator. These were tested twice, 8 days apart, on C8166 cells against HIV-1 NL 4-3 (results are shown in Tables 6 and 7) and on C8166 cells against HIV-1 NDK (results are shown in Table 8).

Please delete Table 3 and replace it with the following table:

Table 3

Antiviral Activity Experiment on C8166 cells with HIV-1 subtype B NL 4-3

Name	Formula	IC_{50} (μM)
SPC3	$(GPGRAF)_8$-K_4-K_2-K-$NHCH_2CH_2COOH$ **(SEQ ID NOS 4 & 11)**	0.5
SPC3 dimer valeric acid	$(GPGRAF)_2$-K-$NHCH_2CH_2CH_2CH_2COOH$ **(SEQ ID NO: 4)**	0.05
SPC3 monomer	GPGRAF **(SEQ ID NO: 4)**	>10
SPC3 monomer valeric acid	GPGRAF-$NHCH_2CH_2CH_2CH_2COOH$ **(SEQ ID NO: 4)**	0.02
RL	$(RQGYSPL)_8$-K_4-K_2-K-$NHCH_2CH_2COOH$ **(SEQ ID NOS 7 & 11)**	0.01
RL dimer	$(RQGYSPL)_2$-K-$NHCH_2CH_2COOH$ **(SEQ ID NO: 7)**	0.02
RL monomer	RQGYSPL **(SEQ ID NO: 7)**	0.5
RL dimer valeric acid	$(RQGYSPL)_2$-K-$NHCH_2CH_2CH_2CH_2COOH$ **(SEQ ID NO: 7)**	0.05
RL monomer valeric acid	RQGYSPL-$NHCH_2CH_2CH_2CH_2COOH$ **(SEQ ID NO: 7)**	0.05
RS	$(RQGYS)_2$-K-$NHCH_2CH_2COOH$ **(SEQ ID NO: 9)**	0.1
RS monomer	RQGYS **(SEQ ID NO: 9)**	0.2
RS dimer valeric acid	$(RQGYS)_2$-K-$NHCH_2CH_2CH_2CH_2COOH$ **(SEQ ID NO: 9)**	0.05
RS monomer valeric acid	RQGYS-$NHCH_2CH_2CH_2CH_2COOH$ **(SEQ ID NO: 9)**	0.2

Please delete Table 4 and replace it with the following table:

Table 4

Experiment on PBL with NL 4-3 strain

Name	Formula	IC_{50} (μM)	IC_{100} (μM)
SPC3	$(GPGRAF)_8$-K_4-K_2-K-$NHCH_2CH_2COOH$ **(SEQ ID NOS 4 & 11)**	0.01	0.1
SPC3 monomer valeric acid	GPGRAF-$NHCH_2CH_2CH_2CH_2COOH$ **(SEQ ID NO: 4)**	0.02	0.1
RL	$(RQGYSPL)_8$-K_4-K_2-K-$NHCH_2CH_2COOH$ **(SEQ ID NOS 7 & 11)**	0.005	0.1
RL dimer	$(RQGYSPL)_2$-K-$NHCH_2CH_2COOH$ **(SEQ ID NO: 7)**	0.01	0.1
RL dimer valeric acid	$(RQGYSPL)_2$-K-$NHCH_2CH_2CH_2CH_2COOH$ **(SEQ ID NO: 7)**	0.005	0.05
RL monomer valeric acid	RQGYSPL-$NHCH_2CH_2CH_2CH_2COOH$ **(SEQ ID NO: 7)**	0.01	1

Please delete Table 5 and replace it with the following table:

Table 5

Experiment on PBMC with HIV-1 89.6 subtype B dualtropic (X4R5)

Name	Formula	IC_{50} (μM)	IC_{100} (μM)
SPC3	$(GPGRAF)_8$-K_4-K_2-K-$NHCH_2CH_2COOH$ **(SEQ ID NOS 4 & 11)**	0.06	0.5
SPC3 dimer valeric acid	$(GPGRAF)_2$-K-$NHCH_2CH_2CH_2CH_2COOH$ **(SEQ ID NO: 4)**	0.008	0.5
SPC3 monomer valeric acid	GPGRAF-$NHCH_2CH_2CH_2CH_2COOH$ **(SEQ ID NO: 4)**	0.01	0.5
RL	$(RQGYSPL)_8$-K_4-K_2-K-$NHCH_2CH_2COOH$ **(SEQ ID NOS 7 & 11)**	0.006	0.05
RL dimer valeric acid	$(RQGYSPL)_2$-K-$NHCH_2CH_2CH_2CH_2COOH$ **(SEQ ID NO: 7)**	0.01	0.5
RL monomer valeric acid	RQGYSPL-$NHCH_2CH_2CH_2CH_2COOH$ **(SEQ ID NO: 7)**	0.01	0.1

Please delete Table 6 and replace it with the following table:

Table 6

Antiviral Activity Experiment on C8166 cells with HIV NL-4-3

GPG	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 µM	-		-	-	-	1
	-		-	-	-	5
1 µM	-		-	-	-	3.8
	-		-	-	-	5.4
0.5 µM	-		-	-	-	7.9
	-		-	-	-	18
0.1µM	-		-	-	+	525
	-		-	-	+	5764
0.05µM	-		-	(+)	+	7330
	-		-	(+)	+	9810
0.01µM	-		(+)	+	++	13850
	-		(+)	+	++	11756
0.005µM	-		+	++	++/T	23810
	-		+	++	++/T	23810
GPG valeric acid	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 µM	-		-	-	-	5.6
	-		-	-	-	3.2
1 µM	-		-	-	-	5.636
	-		-	-	-	4.8
0.5 µM	-		-	-	-	3.5
	-		-	-	-	5.6
0.1µM	-		-	(+)	+	126
	-		-	(+)	+	3810
0.05µM	-		-	(+)	+	1850
	-		-	(+)	+	9867
0.01µM	-		+	+	++	11810
	-		+	+	++	13740
0.005µM	-		+	++	++/T	23810
	-		+	++	++/T	23810
GPGR (SEQ ID NO: 1)	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 µM	-		-	-	-	9.425
	-		-	-	-	3.375
1 µM	-		-	-	+	1103
	-		-	-	+	485
0.5 µM	-		-	-	+	2507
	-		-	-	+	2840
0.1µM	-		(+)	+	+	5810
	-		(+)	+	+	10110
0.05µM	-		+	+	++	2507
	-		+	+	++	13870
0.01µM	-		+	++	++	23810
	-		+	++	++	23810
0.005µM	-		++	++	++/T	23810
	-		++	++	++/T	23810
GPGR (SEQ ID NO: 1) valeric acid	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 µM	-		-	-	-	2.36
	-		-	-	-	2.4
1 µM	-		-	-	+	104
	-		-	-	+	179
0.5 µM	-		-	-	+	105
	-		-	-	+	510
0.1µM	-		(+)	+	+	433

	-		(+)	+	+	507
0.05µM	-		(+)	+	++	9840
	-		(+)	+	++	11830
0.01µM	-		+	++	++	21800
	-		+	++	++	23810
0.005µM	-		+	++	++	23810
	-		+	++	++	23810
GPGRA (SEQ ID NO: 12)	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 µM	-		-	-	-	3.62
	-		-	-	-	13
1 µM	-		-	-	-	2.9
	-		-	-	-	3.2
0.5 µM	-		-	-	-	2.1
	-		-	-	-	2.1
0.1µM	-		(+)	+	+	2838
	-		(+)	+	+	2435
0.05µM	-		(+)	+	++	4230
	-		(+)	+	++	8910
0.01µM	-		+	++	++/T	15650
	-		+	++	++/T	16810
0.005µM	-		+	++	++/T	23810
	-		+	++	++/T	23810
GPGRA (SEQ ID NO: 12) valeric acid	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 µM	-		-	-	-	2.7
	-		-	-	-	1.8
1 µM	-		-	-	-	2.3
	-		-	-	-	1.9
0.5 µM	-		-	-	-	2
	-		-	-	-	2.2
0.1µM	-		(+)	+	+	2352
	-		(+)	+	+	1011
0.05µM	-		(+)	+	+	6830
	-		(+)	+	+	3820
0.01µM	-		+	++	++	13030
	-		+	++	++	13810
0.005µM	-		+	++	++/T	23810
	-		+	++	++/T	23810
SPC3 monomer valeric acid	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 µM	-		-	-	-	3
	-		-	-	-	3
1 µM	-		-	-	(+)	325
	-		-	-	(+)	445
0.5 µM	-		-	(+)	+	1840
	-		-	(+)	+	2830
0.1µM	-		(+)	+	++	11810
	-		(+)	++	++	1507
0.05µM	-		+	++	++	3810
	-		+	++	++	21810
0.01µM	-		+	++	++ /T	21810
	-		+	++	++/T	21810
0.005µM	-		+	++	++ /T	23810
	-		+	++	++/T	23810
SPC3	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 µM	-		-	-	-	3
	-		-	-	-	3

1 µM	- -		- -	- -	(+) (+)	1692 776
0.5 µM	- -		- -	(+) (+)	+ +	5173 4840
0.1µM	- -		(+) (+)	+ ++	++ ++	17810 19850
0.05µM	- -		+ +	++ ++	++ /T ++/T	23810 23810
0.01µM	- -		+ +	++ ++	++ /T ++/T	23810 23810
0.005µM	- -		+ +	++ ++	++ /T ++/T	23810 23810
Cell	- -		- -	- -	- -	3 3
L4-3 1/1000	(+) (+)		+ +	++ ++	++ /T ++/T	23810 23810

Please delete Table 7 and replace it with the following table:

Table 7

Antiviral Activity Experiment on C8166 cells with HIV NL-4-3

GPG	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 µM	- -		- -	- -	- -	2 79
1 µM	- -		- -	- -	(+) (+)	42 62
0.5 µM	- -		- -	- -	(+) (+)	126 165
0.1µM	- -		- -	(+) (+)	+ +	807 1506
0.5µM	- -		- -	(+) (+)	+ +	1810 3810
0.01µM	(+) (+)		(+) (+)	+ +	++ ++	9810 15810

Table 7 (continued)

GPG valeric acid	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 µM	-		-	-	-	60
	-		-	-	-	34
1 µM	-		-	-	-	86
	-		-	-	-	74
0.5 µM	-		-	-	(+)	126
	-		-	-	(+)	44
0.1µM	-		-	(+)	+	108
	-		-	(+)	+	130
0.05µM	-		-	(+)	+	3810
	-		-	(+)	+	2300
0.01µM	-		(+)	+	++	3800
	-		(+)	+	++	23000
GPGR (SEQ ID NO: 1)	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 µM	-		-	-	(+)	152
	-		-	-	(+)	152
1 µM	-		-	-	(+)	316
	-		-	-	(+)	343
0.5 µM	-		-	-	+	23000
	-		-	-	+	15810
0.1µM	-		(+)	+	+	5810
	-		(+)	+	+	23000
0.05µM	(+)		+	+	++	13810
	(+)		+	+	++	12980
0.01µM	(+)		+	++	++	23810
	(+)		+	++	++	23810
GPGR (SEQ ID NO: 1) valeric acid	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 µM	-		-	-	-	2
	-		-	-	-	2
1 µM	-		-	-	-	53
	-		-	-	-	64
0.5 µM	-		-	-	+	2740
	-		-	-	+	2840
0.1µM	-		(+)	+	+	2173
	-		(+)	+	+	9810
0.05µM	-		(+)	+	++	9860
	-		(+)	+	++	17800
0.01µM	-		+	++	++/T	3800
	-		+	++	++	21300
GPGRA (SEQ ID NO: 12)	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 µM	-		-	-	(+)	99
	-		-	-	(+)	100
1 µM	-		-	-	(+)	117
	-		-	-	(+)	119
0.5 µM	-		-	-	+	2070
	-		-	-	+	5410
0.1µM	-		(+)	+	+	2837
	-		(+)	+	++	9310
0.05µM	-		(+)	+	++	4230
	-		(+)	+	++	8910
0.01µM	-		+	++	++/T	15650
	-		+	++	++/T	16810

Table 7 (continued)

GPGRA (SEQ ID NO: 12) valeric acid	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 µM	- -		- -	- -	- -	2.7 3
1 µM	- -		- -	- -	- -	13 10
0.5 µM	- -		- -	- -	(+) (+)	234 576
0.1µM	- -		- -	(+) (+)	+ +	2356 2416
0.05µM	- -		(+) (+)	+ +	+ +	3810 11820
0.01µM	- -		+ +	++ ++	++ ++	13870 11810
Cell	- -		- -	- -	- -	2 6
L4-3 1/1000	(+) (+)		+ +	++ ++	++ /T ++/T ++ /T	23810 15670 19750

Please delete Table 8 and replace it with the following table:

Table 8

Antiviral Activity Experiment on C8166 cells with HIV 1 NDK

GPG	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 µM	- -		- -	- -	+ +	2733 2400
1 µM	- -		(+) (+)	+ +	+ +	2507 3810
0.5 µM	- -		+ +	++ ++	++ ++	21110 23810
0.1µM	- -		+ +	++ ++	++ ++	23810 23810
0.05µM	(+) (+)		+ +	++ ++	++ ++	23810 23810
0.01µM	+ +		+ +	++ ++	++ ++	23810 23810
0.005µM	+ +		+ +	++ ++	++ ++	23810 23810
GPG valeric acid	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 µM	- -		- -	- -	(+) (+)	284 217
1 µM	- -		- -	- -	+ +	2810 1840
0.5 µM	-		-	+	++	2578

	-		-	+	++	3140
0.1µM	-		-	+	++	3507
	-		-	+	++	3670
0.05µM	-		(+)	++	++	11810
	-		(+)	++	++	15879
0.01µM	(+)		+	++	++	23810
	(+)		+	++	++	23810
0.005µM	(+)		+	++	++	23810
	(+)		+	++	++	23810

Table 8 (continued)

GPGR (SEQ ID NO: 1)	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 µM	-		-	+	++	2840
	-		-	+	++	7810
1 µM	-		-	+	++	9870
	-		-	+	++	13890
0.5 µM	-		(+)	++	++	9810
	-		(+)	++	++	15856
0.1µM	-		(+)	++	++	21810
	-		(+)	++	++	23870
0.05µM	-		+	++	++	23810
	-		+	++	++	23810
0.01µM	-		+	++	++	23810
	-		+	++	++	23810
0.005µM	-		+	++	++/T	23810
	-		+	++	++/T	23810
GPGR (SEQ ID NO: 1) valeric acid	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 µM	-		-	(+)	+	3810
	-		-	(+)	+	3810
1 µM	-		-	+	++	2840
	-		-	+	++	3810
0.5 µM	-		-	+	++	7810
	-		-	+	++	3840
0.1µM	-		(+)	++	++	17890
	-		(+)	++	++	23810
0.05µM	-		(+)	++	++	23810
	-		(+)	++	++	23810
0.01µM	(+)		+	++	++	23810
	(+)		+	++	++	23810
0.005µM	(+)		+	++	++	23810
	(+)		+	++	++	23810
GPGRA (SEQ ID NO: 12)	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 µM	-		-	-	+	2726
	-		-	-	+	2070
1 µM	-		-	+	++	3070
	-		-	+	++	2403
0.5 µM	-		-	++	++	2070
	-		-	++	++	5420
0.1µM	-		(+)	++	++	13840
	-		(+)	++	++	9310
0.05µM	-		(+)	++	++	13010
	-		(+)	++	++	10910
0.01µM	(+)		+	++	++	15650
	(+)		+	++	++	16810
0.005µM	(+)		+	++	++	23810

	(+)		+	++	++	23810
GPGRA (SEQ ID NO: 12) valeric acid	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 µM	-		-	-	-	32
	-		-	-	(+)	108
1 µM	-		-	-	+	2000
	-		-	-	+	2403
0.5 µM	-		-	+	++	3810
	-		-	+	++	7810
0.1µM	-		(+)	++	++	5600
	-		(+)	++	++	6400
0.05µM	-		(+)	++	++	3810
	-		(+)	++	++	11789
0.01µM	-		+	++	++	13810
	-		+	++	++	18710
0.005µM	(+)		+	++	++	23810
	(+)		+	++	++	23810

Table 8 (continued)

SPC3 monomer valeric acid	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 µM	-		-	-	-	123
	-		-	-	-	345
1 µM	-		-	-	(+)	1325
	-		-	-	(+)	4345
0.5 µM	-		-	+	++	11840
	-		-	+	++	12240
0.1µM	-		+	++	++	11810
	-		+	++	++	15307
0.05µM	-		+	++	++	23810
	-		+	++	++	21810
0.01µM	-		+	++	++ /T	21810
	-		+	++	++/T	21810
0.005µM	-		+	++	++ /T	23810
	-		+	++	++/T	23810
SPC3	Day 4	P 24 (pg/ml)	Day 5	Day 6	Day 7	P 24 (pg/ml)
5 µM	-		-	-	-	12
	-		-	-	-	240
1 µM	-		-	-	(+)	1692
	-		-	-	(+)	3776
0.5 µM	-		-	+	++	15173
	-		-	+	++	12840
0.1µM	-		(+)	+	++	18810
	-		(+)	++	++	20850
0.05µM	-		+	++	++ /T	23810
	-		+	++	++/T	23810
0.01µM	-		+	++	++ /T	23810
	-		+	++	++/T	23810
0.005µM	-		+	++	++ /T	23810
	-		+	++	++/T	23810

Cell	-		-	-	-	
	-		-	-	-	
	(+)		++	++	++ /T	19657
	(+)		++	++	++/T	23810

L4-3 1/1000						

Please delete Table 9 and replace it with the following table:

Table 9

Antiviral Activity Experiment on C8166 cells with HIV-1 subtype B NL 4-3

Name	Formula	IC_{50} (μM)	IC_{100} (μM)
GPG	GPG	0.01 0.01	5 5
GPG valeric acid	GPG-$NHCH_2CH_2CH_2CH_2COOH$	0.01 0.01	0.5 1
GPGR **(SEQ ID NO: 1)**	GPGR **(SEQ ID NO: 1)**	0.06 0.1	5 >5
GPGR **(SEQ ID NO: 1)** valeric acid	GPGR-$NHCH_2CH_2CH_2CH_2COOH$ **(SEQ ID NO: 1)**	0.03 0.01	5 1
GPGRA **(SEQ ID NO: 12)**	GPGRA **(SEQ ID NO: 12)**	0.03 0.02	0.5 >5
GPGRA **(SEQ ID NO: 12)** valeric acid	GPGRA-$NHCH_2CH_2CH_2CH_2COOH$ **(SEQ ID NO: 12)**	0.01 0.01	0.1 1
SPC3 monomer valeric acid	GPGRAF-$NHCH_2CH_2CH_2CH_2COOH$ **(SEQ ID NO: 4)**	0.05	5
SPC3	$(GPGRAF)_8$-K_4-K_2-K-$NHCH_2CH_2COOH$ **(SEQ ID NOS 4 & 11)**	0.5	5

Please delete Table 10 and replace it with the following table:

Table 10

Antiviral Activity Experiment on C8166 cells with HIV 1 NDK

Name	Formula	IC_{50} (μM)	IC_{100} (μM)
GPG	GPG	0.5	>5
GPG valeric acid	GPG-$NHCH_2CH_2CH_2CH_2COOH$	0.02	5
GPGR **(SEQ ID NO: 1)**	GPGR **(SEQ ID NO: 1)**	0.5	>5
GPGR **(SEQ ID NO: 1)** valeric acid	GPGR-$NHCH_2CH_2CH_2CH_2COOH$ **(SEQ ID NO: 1)**	0.3	>5
GPGRA **(SEQ ID NO: 12)**	GPGRA **(SEQ ID NO: 12)**	0.04	>5
GPGRA **(SEQ ID NO: 12)** valeric acid	GPGRA-$NHCH_2CH_2CH_2CH_2COOH$ **(SEQ ID NO: 12)**	>5	5
SPC3 monomer valeric acid	GPGRAF-$NHCH_2CH_2CH_2CH_2COOH$ **(SEQ ID NO: 4)**	0.2	5
SPC3	$(GPGRAF)_8$-K_4-K_2-K-$NHCH_2CH_2COOH$ **(SEQ ID NOS 4 & 11)**	0.6	5